Pancreatic Cancer Research

ResearcherUniversity of North Carolina at Chapel HillNo recent work listed

Bert H. O’Neil

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7032-7453; OpenAlex author ID A5010925062. Sources: ClinicalTrials.gov.

Their work

Papers
15 (first author 1, last author 2)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
51
Papers, trials and grants by year

2004: 1 trial · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: none · 2012: 1 paper · 2013: none · 2014: none · 2015: 3 papers · 2016: 2 papers · 2017: 1 paper · 2018: 3 papers · 2019: 2 papers · 2020: 2 papers · 2021: none · 2022: none · 2023: 1 paper

Papers 15

  1. Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198). Co-author DOI 10.1016/j.ejca.2023.02.030↗
  2. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated … Co-author DOI 10.1007/s10637-019-00824-1↗
  3. Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-0489↗
  4. Phase 1 study of EUS-guided photodynamic therapy for locally advanced pancreatic cancer. Co-author DOI 10.1016/j.gie.2018.09.007↗
  5. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study. Co-author DOI 10.1186/s12885-019-5630-4↗
  6. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancrea… Co-author DOI 10.1097/coc.0000000000000409↗
  7. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX. Last author DOI 10.1158/1078-0432.ccr-18-1472↗
  8. Homologous Recombination Deficiency in Patients With Pancreatic Ductal Adenocarcinoma and Response to Chemotherapy. Last author DOI 10.1200/po.17.00087↗
  9. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer. Co-author DOI 10.21873/anticanres.11985↗
  10. A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic … First author DOI 10.1007/s00280-016-2981-2↗
  11. Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts. Co-author DOI 10.1371/journal.pone.0147113↗
  12. (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior ther… Co-author DOI 10.1016/j.ejca.2015.06.119↗
  13. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreate… Co-author DOI 10.1093/annonc/mdv264↗
  14. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreate… Co-author DOI 10.1093/annonc/mdv477↗
  15. Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. Co-author DOI 10.1002/cncr.27592↗

Trials 1

  1. Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer Principal investigator NCT00266097↗

Closest collaborators

The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Safi Shahda · 8 shared papers, 2017–2020 · strength 0.77
  2. Steven J. Cohen · 7 shared papers, 2015–2023 · strength 0.53
  3. Amikar Sehdev · 4 shared papers, 2017–2019 · strength 0.39
  4. Olumide B. Gbolahan · 3 shared papers, 2018–2019 · strength 0.30
  5. Wells A. Messersmith · 4 shared papers, 2015–2020 · strength 0.27
  6. Jordan D. Berlin · 4 shared papers, 2015–2020 · strength 0.23
  7. Efrat Dotan · 2 shared papers, 2020 · strength 0.20
  8. Heinz‐Josef Lenz · 2 shared papers, 2020 · strength 0.20
  9. Dana Backlund Cardin · 2 shared papers, 2020 · strength 0.20
  10. Tanios Bekaii‐Saab · 2 shared papers, 2012–2023 · strength 0.19
  11. Michael Garrett House · 2 shared papers, 2018–2019 · strength 0.19
  12. Patrick Joseph Loehrer · 1 shared paper, 2023 · strength 0.17
  13. Walid Labib Shaib · 1 shared paper, 2023 · strength 0.17
  14. Bassel F. El‐Rayes · 1 shared paper, 2023 · strength 0.17
  15. Colin D. Weekes · 2 shared papers, 2016–2020 · strength 0.15
  16. Sarah Lindsey Davis · 1 shared paper, 2020 · strength 0.11
  17. Hai Salfity · 1 shared paper, 2018 · strength 0.10
  18. Neda Hashemi‐Sadraei · 1 shared paper, 2018 · strength 0.10
  19. Igor A. Astsaturov · 1 shared paper, 2020 · strength 0.10
  20. Kumaresan Sandrasegaran · 1 shared paper, 2019 · strength 0.09
  21. Nicholas Joseph Zyromski · 1 shared paper, 2019 · strength 0.09
  22. John M. DeWitt · 1 shared paper, 2019 · strength 0.09
  23. Lawrence Leichman · 2 shared papers, 2015–2016 · strength 0.09
  24. Neelakanta Dadi · 1 shared paper, 2017 · strength 0.09
  25. Deirdre Jill Cohen · 2 shared papers, 2015 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.